Skip to main navigation Skip to search Skip to main content

Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets

  • John M Bennett
  • , Sunil K Narwal
  • , Stephanie Kabeche
  • , Daniel Abegg
  • , Vandana Thathy
  • , Fiona Hackett
  • , Tomas Yeo
  • , Veronica L Li
  • , Ryan Muir
  • , Franco Faucher
  • , Scott Lovell
  • , Michael J Blackman
  • , Alexander Adibekian
  • , Ellen Yeh
  • , David A Fidock
  • , Matthew Bogyo
  • Stanford University
  • Columbia University Irving Medical Center
  • University of Illinois at Chicago
  • Francis Crick Institute
  • Department of Oral Pathology

Research output: Contribution to journal › Article › peer-review

3   Link opens in a new tab Citations (SciVal)

Abstract

Malaria, caused by Plasmodium falciparum, remains a significant health burden. One major barrier for developing antimalarial drugs is the ability of the parasite to rapidly generate resistance. We previously demonstrated that salinipostin A (SalA), a natural product, potently kills parasites by inhibiting multiple lipid metabolizing serine hydrolases, a mechanism that results in a low propensity for resistance. Given the difficulty of employing natural products as therapeutic agents, we synthesized a small library of lipidic mixed alkyl/aryl phosphonates as bioisosteres of SalA. Two constitutional isomers exhibited divergent antiparasitic potencies that enabled the identification of therapeutically relevant targets. The active compound kills parasites through a mechanism that is distinct from both SalA and the pan-lipase inhibitor orlistat and shows synergistic killing with orlistat. Our compound induces only weak resistance, attributable to mutations in a single protein involved in multidrug resistance. These data suggest that mixed alkyl/aryl phosphonates are promising, synthetically tractable antimalarials.

Original languageEnglish
Pages (from-to)1714-1728.e10
JournalCell Chemical Biology
Volume31
Issue number9
Early online date12 Aug 2024
DOIs
Publication statusPublished - 19 Sept 2024

Funding

This work was supported in part by the NIH ( R33 AI127581 , to DAF and MB, R01 AI109023 to D.A.F) and by Department of Defense grant ( W81XWH2210520 to D.F. and M.B.). V.L.L. was supported by NIH training grant T32 GM113854 . The work was also supported by funding to M.J.B. from the Wellcome Trust ( 220318/A/20/Z ) and the Francis Crick Institute ( https://www.crick.ac.uk/ ) which receives its core funding from Cancer Research UK ( CC2129 ), the UK Medical Research Council ( CC2129 ), and the Wellcome Trust ( CC2129 ).

FundersFunder number
Medical Research Council
Francis Crick Institute
Cancer Research UKCC2129
U.S. Department of DefenseW81XWH2210520, T32 GM113854, W81XWII2210520
National Institutes of HealthR33 AH27581, R01 AI109023, R33 AI127581
Bill & Melinda Gates FoundationINV-033538
The Wellcome Trust220318/A/20/Z

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Plasmodium falciparum
  • activity-based probes
  • alky/aryl phosphonates
  • covalent probes
  • drug resistance
  • lipid metabolism
  • serine hydrolases

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets'. Together they form a unique fingerprint.

Cite this